Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate (Q34550827)
scientific article
Language:
(P31) (Q13442814)
(P304) 3776-3783
(P407) (Q1860)
(P433) 18
(P478) 22
(P577) Wednesday, September 1, 2004
(P921) (Q212961)
(Q412197)
(P1433) (Q400292)
(P1476) "Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate" (language: en)
(P2093) Caio M Rocha Lima
Mark R Green
Robert Rotche
Wilson H Miller
G Mark Jeffrey
Laura A Cisar
Adele Morganti
Nicoletta Orlando
Gabriela Gruia
Langdon L Miller
other details
description scientific article

External Links